Nisa Investment Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15
| Closed | – | – | 3096 |
|
|
2024
Q4 | $0 | Buy |
+15
| New | – | ﹤0.01% | 3093 |
|
|
2024
Q3 | – | Sell |
-15
| Closed | – | – | 3095 |
|
|
2024
Q2 | $0 | Hold |
15
| – | – | ﹤0.01% | 3016 |
|
|
2024
Q1 | $222 | Hold |
15
| – | – | ﹤0.01% | 2622 |
|
|
2023
Q4 | $201 | Hold |
15
| – | – | ﹤0.01% | 2557 |
|
|
2023
Q3 | $185 | Buy |
+15
| New | +$182 | ﹤0.01% | 2677 |
|
|
2018
Q2 | – | Sell |
-26,183
| Closed | -$207K | – | 1932 |
|
|
2018
Q1 | $207K | Buy |
26,183
+18,811
| +255% | +$156K | ﹤0.01% | 1228 |
|
|
2017
Q4 | $59K | Buy |
+7,372
| New | +$68.7K | ﹤0.01% | 1445 |
|
|
2017
Q1 | – | Sell |
-483
| Closed | -$16K | – | 1930 |
|
|
2016
Q4 | $16K | Hold |
483
| – | – | ﹤0.01% | 1708 |
|
|
2016
Q3 | $24K | Buy |
483
+267
| +124% | +$11.1K | ﹤0.01% | 1598 |
|
|
2016
Q2 | $9K | Hold |
216
| – | – | ﹤0.01% | 1805 |
|
|
2016
Q1 | $14K | Buy |
+216
| New | +$11.3K | ﹤0.01% | 1720 |
|
Nisa Investment Advisors's MACK Position: Q1 2025 in Review
Nisa Investment Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2025, closing a stake of 15 shares.
Nisa Investment Advisors first reported a position in MACK in Q1 2016 and held it in 11 quarters. The position peaked at $207K in Q1 2018. 1 fund tracked by Wall St. Rank holds MACK as of Q1 2025.
- Nisa Investment Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
- Nisa Investment Advisors sold 15 Merrimack Pharmaceuticals, Inc. shares in Q1 2025.
- Nisa Investment Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2016 and held it in 11 quarters.
- Nisa Investment Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $207K in Q1 2018.
- 1 fund tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2025.
Based on Nisa Investment Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.